DAS181: A Broad-Spectrum Antiviral Therapeutic for Treatment of Influenza A & B
Award Notice Posted
- Solicitation number
- BAA-11-100-SOL-00021
- Agency
-
Immediate Office of the Secretary
Department of Health and Human Services
- Awarded
- to Ansun Biopharma, Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- HHSO100201200011C Federal IDV award
- NAICS code
- 541711 Research and Development in Biotechnology
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
Notice text
This announcement is for the award of a Cost Plus Fixed Fee (CPFF) type Research and Development contract to NexBio, Incorporated for the development DAS181, A Broad-Spectrum Antiviral Therapeutic for Treatment of Influenza A and B Virus Infections under the procedures of the subject Broad Agency Announcement (BAA). The major goal of this contract is to successfully complete a Phase 2B clinical trial which will advance DAS181 towards NDA filing and approval for treatment of influenza.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Point of Care (POC) Influenza Antiviral Susceptibility Test | Award Notice | |
| This notice | Award Notice | |
| BARDA Broad Agency Announcement (BAA) for Advanced Research and Development of Personal Protective Equipment, Ventilators, and Diagnostics | Award Notice |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity